19 Matching Annotations
  1. Last 7 days
    1. Homozygous inactivation of CHEK2 is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs

      [Paper-level Aggregated] PMCID: PMC5111006

      Evidence Type(s): Oncogenic, Functional, Predisposing, Predictive

      Justification: Oncogenic: The mutation p.R474C in CHEK2 was shown to be unstable and poorly activated in response to DNA damage, suggesting a contributory role in familial cancer cases. Functional: The analysis indicated that p.R474C disrupts a salt bridge critical for protein stability and function, affecting the protein's activation upon DNA damage. Predisposing: The presence of the CHEK2 mutation in a familial context, along with the development of multiple primary cancers in the patients, suggests a predisposition to cancer associated with this variant. Predictive: The use of prediction models indicated that p.R474C was "disease causing" and likely interfered with protein function, supporting its predictive value in assessing cancer risk.

      Gene→Variant (gene-first): EGFR(1956):L858R TP53(7157):p.P72R BRCA2(675):p.V2466A TP53(7157):rs1042522 MSH6(2956):rs1042821 EPCAM(4072):rs1126497 BRCA2(675):rs169547 PMS2(5395):rs1805323 PMS2(5395):rs2228006 MSH2(4436):rs2303424 FCGRT(2217):p.R210 FCGRT(2217):p.R210Q CHEK2(11200):p.R474 CHEK2(11200):p.R474C PIWIL3(440822):rs11703684 SAA2(6289):rs2468844 KCNJ11(3767):rs5215 KCNJ11(3767):rs5219 ABCC8(6833):rs757110

      Genes: EGFR(1956) TP53(7157) BRCA2(675) MSH6(2956) EPCAM(4072) PMS2(5395) MSH2(4436) FCGRT(2217) CHEK2(11200) PIWIL3(440822) SAA2(6289) KCNJ11(3767) ABCC8(6833)

      Variants: L858R p.P72R p.V2466A rs1042522 rs1042821 rs1126497 rs169547 rs1805323 rs2228006 rs2303424 p.R210 p.R210Q p.R474 p.R474C rs11703684 rs2468844 rs5215 rs5219 rs757110

    2. In clinical practice, there are a number of cancer patients with clear family histories, but the patients lack mutations in known familial cancer syndrome genes. Recent advances in genomic technologies have enhanced the

      [Paragraph-level] PMCID: PMC5111006 Section: ABSTRACT PassageIndex: 1

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage indicates that the homozygous CHEK2 variant p.R474C was contributory to familial cancer, and the inactivation of CHEK2 in mice led to cancers in multiple organs, suggesting a role in tumor development. Functional: The variant p.R474C alters the tertiary structure of the CHK2 protein by disrupting a salt bridge, and subsequent analysis showed that it was unstable and scarcely activated, indicating a change in molecular function.

      Gene→Variant (gene-first): 11200:p.R474 11200:p.R474C

      Genes: 11200

      Variants: p.R474 p.R474C

    3. Among the variants detected in the runs of homozygosity common to both siblings, five were recorded as disease-associated variants in the HGMD public entries. However, they are related to diabetes or insulin secretion (r

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 18

      Evidence Type(s): Diagnostic, Predisposing

      Justification: Diagnostic: The passage states that the variants are recorded as disease-associated variants, indicating their use in defining or classifying diseases such as diabetes, carotid intima media thickness, and oligospermia. Predisposing: The variants mentioned are associated with inherited conditions, suggesting they confer an inherited risk for developing diseases, although the germline nature is implied rather than explicitly stated.

      Gene→Variant (gene-first): 440822:rs11703684 6289:rs2468844 3767:rs5215 3767:rs5219 6833:rs757110

      Genes: 440822 6289 3767 6833

      Variants: rs11703684 rs2468844 rs5215 rs5219 rs757110

    4. We surveyed variants in potential hereditary loci including those in TP53 (causative gene for Li-Fraumeni syndrome), BRCA2 (causative gene for hereditary breast/ovarian cancer), and mismatch repair genes (MSH2, MSH6, PMS

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 17

      Evidence Type(s): Predisposing, Diagnostic

      Justification: Predisposing: The passage discusses variants in hereditary loci, specifically mentioning TP53 and BRCA2, which are associated with inherited cancer syndromes, indicating a potential inherited risk for developing disease. Diagnostic: The passage mentions the classification of variants as "Benign" or of "Uncertain significance," which relates to their use in defining or classifying disease risk or status.

      Gene→Variant (gene-first): 7157:p.P72R 675:p.V2466A 7157:rs1042522 2956:rs1042821 4072:rs1126497 675:rs169547 5395:rs1805323 5395:rs2228006 4436:rs2303424

      Genes: 7157 675 2956 4072 5395 4436

      Variants: p.P72R p.V2466A rs1042522 rs1042821 rs1126497 rs169547 rs1805323 rs2228006 rs2303424

    5. CHK2 is a cell cycle checkpoint regulator activated by DNA damage. The above analysis and the function of CHK2 suggest that CHEK2 is a contributory gene for this familial case. We therefore examined the function of CHK2

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 15

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses how the p.R474C variant alters the molecular function of the CHK2 protein, demonstrating that it is poorly expressed and activated by DNA damage compared to the wild-type protein. Oncogenic: The context implies that the p.R474C variant contributes to tumor development or progression by affecting the function of a cell cycle checkpoint regulator, which is critical in the context of cancer biology.

      Gene→Variant (gene-first): 11200:p.R474C

      Genes: 11200

      Variants: p.R474C

    6. CHK2 p.R474C Protein Is Poorly Activated in the Cell upon DNA Damage

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 14

      Evidence Type(s): Functional

      Justification: Functional: The passage indicates that the p.R474C variant affects the activation of the CHK2 protein in response to DNA damage, suggesting an alteration in its molecular function.

      Gene→Variant (gene-first): 11200:p.R474C

      Genes: 11200

      Variants: p.R474C

    7. The tertiary structure of FCGRT-immunoglobulin Fc fragment complex was determined. p.R210 contacts the carboxyl terminus of the immunoglobulin Fc fragment. Although there is a salt bridge between p.R210 and the Fc fragme

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 12

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the variant p.R210 and its substitution p.R210Q relate to the structure and potential function of the protein, indicating that p.R210Q is not likely to affect the function and structure of the protein.

      Gene→Variant (gene-first): 2217:p.R210 2217:p.R210Q

      Genes: 2217

      Variants: p.R210 p.R210Q

    8. Second, we examined how the amino acid substitutions affect the tertiary structure of the proteins. The tertiary structure of the inactive CHK2 homodimer (PDB code: 3i6w) is shown in Figure 4B. p.R474 is located away fro

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses how the variant p.R474C alters the salt bridge formation and is likely to make the protein unstable, indicating an alteration in molecular function. Oncogenic: The variant p.R474C is described as "disease causing" and likely interferes with protein function, suggesting a role in tumor development or progression.

      Gene→Variant (gene-first): 11200:p.R474 11200:p.R474C

      Genes: 11200

      Variants: p.R474 p.R474C

    9. First, the effects of these missense variants were predicted using the Variant Effect Predictor at Ensembl, for which SIFT (Sorting Intolerant from Tolerant) and PolyPhen (Polymorphism Phenotyping) are used. Three varian

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 10

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the variant p.R474 in CHEK2 was analyzed for its effect on protein function based on evolutionary conservation, indicating that it alters molecular or biochemical function.

      Gene→Variant (gene-first): 11200:p.R474

      Genes: 11200

      Variants: p.R474

    10. The female patient, FL2, was 6 years older than the male patient. At the age of 38, she was diagnosed with uterine myoma and developed multiple primary lung cancer at the age of 60 with no history of smoking. Three prima

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 4

      Evidence Type(s): Oncogenic

      Justification: Oncogenic: The passage discusses the presence of the L858R mutation in the context of lung cancer, indicating its potential role in tumor development or progression.

      Gene→Variant (gene-first): 1956:L858R

      Genes: 1956

      Variants: L858R

    11. In clinical practice, there are a number of cancer patients with clear family histories, but the patients lack mutations in known familial cancer syndrome genes. Recent advances in genomic technologies have enhanced the

      [Paragraph-level] PMCID: PMC5111006 Section: ABSTRACT PassageIndex: 1

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The passage indicates that the homozygous CHEK2 variant p.R474C was contributory to familial cancer, and the inactivation of CHEK2 in mice led to cancers in multiple organs, suggesting a role in tumor development. Functional: The variant p.R474C alters the tertiary structure of the CHK2 protein by disrupting a salt bridge, and subsequent analysis showed that it was unstable and scarcely activated, indicating a change in molecular function.

      Gene→Variant (gene-first): 11200:p.R474 11200:p.R474C

      Genes: 11200

      Variants: p.R474 p.R474C

    12. Among the variants detected in the runs of homozygosity common to both siblings, five were recorded as disease-associated variants in the HGMD public entries. However, they are related to diabetes or insulin secretion (r

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 18

      Evidence Type(s): Diagnostic, Predisposing

      Justification: Diagnostic: The passage states that the variants are recorded as disease-associated variants, indicating their use in defining or classifying diseases such as diabetes, carotid intima media thickness, and oligospermia. Predisposing: The variants mentioned are associated with inherited conditions, suggesting they confer an inherited risk for developing diseases, although the germline nature is implied rather than explicitly stated.

      Gene→Variant (gene-first): 440822:rs11703684 6289:rs2468844 3767:rs5215 3767:rs5219 6833:rs757110

      Genes: 440822 6289 3767 6833

      Variants: rs11703684 rs2468844 rs5215 rs5219 rs757110

    13. We surveyed variants in potential hereditary loci including those in TP53 (causative gene for Li-Fraumeni syndrome), BRCA2 (causative gene for hereditary breast/ovarian cancer), and mismatch repair genes (MSH2, MSH6, PMS

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 17

      Evidence Type(s): Predisposing, Diagnostic

      Justification: Predisposing: The passage discusses variants in hereditary loci, specifically mentioning TP53 and BRCA2, which are associated with inherited cancer syndromes, indicating a potential inherited risk for developing disease. Diagnostic: The passage mentions the classification of variants as "Benign" or of "Uncertain significance," which relates to their use in defining or classifying disease risk or status.

      Gene→Variant (gene-first): 7157:p.P72R 675:p.V2466A 7157:rs1042522 2956:rs1042821 4072:rs1126497 675:rs169547 5395:rs1805323 5395:rs2228006 4436:rs2303424

      Genes: 7157 675 2956 4072 5395 4436

      Variants: p.P72R p.V2466A rs1042522 rs1042821 rs1126497 rs169547 rs1805323 rs2228006 rs2303424

    14. CHK2 is a cell cycle checkpoint regulator activated by DNA damage. The above analysis and the function of CHK2 suggest that CHEK2 is a contributory gene for this familial case. We therefore examined the function of CHK2

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 15

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses how the p.R474C variant alters the molecular function of the CHK2 protein, demonstrating that it is poorly expressed and activated by DNA damage compared to the wild-type protein. Oncogenic: The context implies that the p.R474C variant contributes to tumor development or progression by affecting the function of a cell cycle checkpoint regulator, which is critical in the context of cancer biology.

      Gene→Variant (gene-first): 11200:p.R474C

      Genes: 11200

      Variants: p.R474C

    15. CHK2 p.R474C Protein Is Poorly Activated in the Cell upon DNA Damage

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 14

      Evidence Type(s): Functional

      Justification: Functional: The passage indicates that the p.R474C variant affects the activation of the CHK2 protein in response to DNA damage, suggesting an alteration in its molecular function.

      Gene→Variant (gene-first): 11200:p.R474C

      Genes: 11200

      Variants: p.R474C

    16. The tertiary structure of FCGRT-immunoglobulin Fc fragment complex was determined. p.R210 contacts the carboxyl terminus of the immunoglobulin Fc fragment. Although there is a salt bridge between p.R210 and the Fc fragme

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 12

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the variant p.R210 and its substitution p.R210Q relate to the structure and potential function of the protein, indicating that p.R210Q is not likely to affect the function and structure of the protein.

      Gene→Variant (gene-first): 2217:p.R210 2217:p.R210Q

      Genes: 2217

      Variants: p.R210 p.R210Q

    17. Second, we examined how the amino acid substitutions affect the tertiary structure of the proteins. The tertiary structure of the inactive CHK2 homodimer (PDB code: 3i6w) is shown in Figure 4B. p.R474 is located away fro

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 11

      Evidence Type(s): Functional, Oncogenic

      Justification: Functional: The passage discusses how the variant p.R474C alters the salt bridge formation and is likely to make the protein unstable, indicating an alteration in molecular function. Oncogenic: The variant p.R474C is described as "disease causing" and likely interferes with protein function, suggesting a role in tumor development or progression.

      Gene→Variant (gene-first): 11200:p.R474 11200:p.R474C

      Genes: 11200

      Variants: p.R474 p.R474C

    18. First, the effects of these missense variants were predicted using the Variant Effect Predictor at Ensembl, for which SIFT (Sorting Intolerant from Tolerant) and PolyPhen (Polymorphism Phenotyping) are used. Three varian

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 10

      Evidence Type(s): Functional

      Justification: Functional: The passage discusses how the variant p.R474 in CHEK2 was analyzed for its effect on protein function based on evolutionary conservation, indicating that it alters molecular or biochemical function.

      Gene→Variant (gene-first): 11200:p.R474

      Genes: 11200

      Variants: p.R474

    19. The female patient, FL2, was 6 years older than the male patient. At the age of 38, she was diagnosed with uterine myoma and developed multiple primary lung cancer at the age of 60 with no history of smoking. Three prima

      [Paragraph-level] PMCID: PMC5111006 Section: RESULTS PassageIndex: 4

      Evidence Type(s): Oncogenic

      Justification: Oncogenic: The passage discusses the presence of the L858R mutation in the context of lung cancer, indicating its potential role in tumor development or progression.

      Gene→Variant (gene-first): 1956:L858R

      Genes: 1956

      Variants: L858R